Journal Article Review Ahead of print
PubMed: 41478859 DOI: 10.1038/s41585-025-01117-4
Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.
Nat Rev Urol
Authors: Michael V Ortiz, Francis S P L Wens, Andrew L Hong, Paola Quarello, Arnauld C Verschuur, Elisabeth T Tracy, Najat C Daw, Jeffrey S Dome, Amy L Walz, Julia Sprokkerieft, Godelieve A M Tytgat, Alex Kentsis, Jaime Libes-Bander, Peter J Schoettler, Daniela Perotti, Jarno Drost, Rajkumar Venkatramani, James I Geller, Marry M van den Heuvel-Eibrink
Affiliations
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- Department of Pediatrics, Emory University School of Medicine, and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
- Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
- Department of Public Health and Pediatrics Sciences, University of Turin, Turin, Italy.
- Department of Pediatric Hemato-Oncology, La Timone Childrens Hospital, APHM, Marseille, France.
- Division of Pediatric Surgery, UNC Children's Hospital, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Center for Cancer and Blood Disorders, Children's National Hospital and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Department of Pediatrics, Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
- Department of Pediatric Hematology-Oncology, Arnold Palmer Hospital for Children, Orlando, FL, USA.
- Department of Pediatrics and Adolescent Medicine, Division of Hematology-Oncology, Mayo Clinic, Rochester, MN, USA.
- Predictive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
- Oncode Institute, Utrecht, The Netherlands.
- Division Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA, Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
- Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
Paediatric kidney tumours are generally associated with a favourable survival rate. Most children are diagnosed with Wilms tumour, which has a 90% long-term survival rate with conventional front-line and salvage therapies. However, treatments and outcomes of children with relapsed non-Wilms tumours, such as malignant rhabdoid tumour of the kidney, renal-cell carcinoma (including renal medullary carcinoma), clear-cell sarcoma of the kidney, anaplastic sarcoma of the kidney and congenital mesoblastic nephroma are not well defined. Several of these non-Wilms tumours include unfavourable prognostic subtypes. Currently available data on non-Wilms tumours support advancing studies that pivot from conventional strategies towards disease-specific, biologically driven novel treatments to improve outcomes for each of these rare childhood kidney tumours.
MeSH
Cells, Kidney, Sarcoma, Adolescent, Wilms Tumor, Therapeutics, Child, Survival Rate